PL371415A1 - Treatment of male sexual dysfunction - Google Patents
Treatment of male sexual dysfunctionInfo
- Publication number
- PL371415A1 PL371415A1 PL03371415A PL37141503A PL371415A1 PL 371415 A1 PL371415 A1 PL 371415A1 PL 03371415 A PL03371415 A PL 03371415A PL 37141503 A PL37141503 A PL 37141503A PL 371415 A1 PL371415 A1 PL 371415A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- sexual dysfunction
- male sexual
- male
- dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202282.0A GB0202282D0 (en) | 2002-01-31 | 2002-01-31 | Treatment of male sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
PL371415A1 true PL371415A1 (en) | 2005-06-13 |
Family
ID=9930155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03371415A PL371415A1 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1470115A1 (en) |
JP (3) | JP2005525321A (en) |
KR (2) | KR20080011232A (en) |
CN (1) | CN100500658C (en) |
AU (1) | AU2003201471B2 (en) |
BR (1) | BR0307337A (en) |
CA (1) | CA2474590A1 (en) |
GB (1) | GB0202282D0 (en) |
HK (1) | HK1073109A1 (en) |
IL (2) | IL162822A0 (en) |
MX (1) | MXPA04007434A (en) |
NZ (1) | NZ546408A (en) |
PL (1) | PL371415A1 (en) |
TW (1) | TW200302732A (en) |
WO (1) | WO2003064402A1 (en) |
ZA (1) | ZA200405208B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3646871A1 (en) * | 2018-10-30 | 2020-05-06 | SEROJAC PME Handels GmbH | Treatment and prevention of premature ejaculation (pe) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
AU690534B2 (en) * | 1992-12-23 | 1998-04-30 | Merck & Co., Inc. | Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
US5693805A (en) * | 1993-03-12 | 1997-12-02 | Merck & Co., Inc. | Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists |
GB0007884D0 (en) | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
US20020028799A1 (en) * | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-01-31 GB GBGB0202282.0A patent/GB0202282D0/en not_active Ceased
-
2003
- 2003-01-20 WO PCT/IB2003/000140 patent/WO2003064402A1/en active Application Filing
- 2003-01-20 BR BR0307337-8A patent/BR0307337A/en not_active IP Right Cessation
- 2003-01-20 CA CA002474590A patent/CA2474590A1/en not_active Abandoned
- 2003-01-20 AU AU2003201471A patent/AU2003201471B2/en not_active Expired
- 2003-01-20 CN CNB038030535A patent/CN100500658C/en not_active Expired - Lifetime
- 2003-01-20 MX MXPA04007434A patent/MXPA04007434A/en active IP Right Grant
- 2003-01-20 NZ NZ546408A patent/NZ546408A/en not_active IP Right Cessation
- 2003-01-20 PL PL03371415A patent/PL371415A1/en not_active Application Discontinuation
- 2003-01-20 IL IL16282203A patent/IL162822A0/en unknown
- 2003-01-20 JP JP2003564025A patent/JP2005525321A/en not_active Ceased
- 2003-01-20 KR KR1020077029747A patent/KR20080011232A/en not_active Application Discontinuation
- 2003-01-20 EP EP03700164A patent/EP1470115A1/en not_active Withdrawn
- 2003-01-20 KR KR1020047011672A patent/KR100829262B1/en not_active IP Right Cessation
- 2003-01-27 TW TW092101731A patent/TW200302732A/en unknown
-
2004
- 2004-06-30 ZA ZA2004/05208A patent/ZA200405208B/en unknown
- 2004-07-01 IL IL162822A patent/IL162822A/en active IP Right Grant
-
2005
- 2005-07-11 HK HK05105801.3A patent/HK1073109A1/en not_active IP Right Cessation
-
2010
- 2010-03-30 JP JP2010079241A patent/JP2010209075A/en not_active Withdrawn
-
2013
- 2013-02-28 JP JP2013038357A patent/JP2013151511A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2003201471B2 (en) | 2009-03-26 |
JP2005525321A (en) | 2005-08-25 |
BR0307337A (en) | 2004-12-07 |
IL162822A0 (en) | 2005-11-20 |
CA2474590A1 (en) | 2003-08-07 |
KR20040079958A (en) | 2004-09-16 |
KR20080011232A (en) | 2008-01-31 |
IL162822A (en) | 2010-11-30 |
TW200302732A (en) | 2003-08-16 |
JP2013151511A (en) | 2013-08-08 |
HK1073109A1 (en) | 2005-09-23 |
NZ546408A (en) | 2007-10-26 |
CN1625553A (en) | 2005-06-08 |
GB0202282D0 (en) | 2002-03-20 |
ZA200405208B (en) | 2005-08-31 |
EP1470115A1 (en) | 2004-10-27 |
WO2003064402A1 (en) | 2003-08-07 |
CN100500658C (en) | 2009-06-17 |
MXPA04007434A (en) | 2004-10-11 |
JP2010209075A (en) | 2010-09-24 |
KR100829262B1 (en) | 2008-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL377729A1 (en) | Method of the treatment of sexual dysfunction | |
IL153492A0 (en) | Treatment of male sexual dysfunction | |
AU2003248888A8 (en) | Peptide composition for treatment of sexual dysfunction | |
IL137569A0 (en) | Treatment of female sexual dysfunction | |
GB0225908D0 (en) | Treatment of female sexual dysfunction | |
ZA200410009B (en) | Compositions and methods for ameliorating of human female sexual dysfunction | |
AU2003219981A1 (en) | Benzimidazole-derivatives for the treatment of sexual dysfunction | |
AU2002238106A1 (en) | Melanocortin metallopeptides for treatment of sexual dysfunction | |
GB2408558B (en) | Treatment of pipes | |
IL162154A0 (en) | Prostagandin composition for the treatment of erectile dysfunction | |
EP1648430A4 (en) | Treatment of premature ejaculation | |
GB2386555B (en) | Treatment of female sexual dysfunction | |
IL166273A0 (en) | Methods of treatment of male erectile dysfunction | |
IL162455A0 (en) | Compounds for the treatment of sexual dysfunction | |
IL155775A0 (en) | Treatment of male sexual dysfunction | |
PL362980A1 (en) | Treatment of sexual dysfunction | |
AU2003260818A8 (en) | Treatment of immune system dysfunction | |
AP2004003174A0 (en) | Treatment of water | |
GB0202282D0 (en) | Treatment of male sexual dysfunction | |
GB0108730D0 (en) | Treatment of male sexual dysfunction | |
GB0108483D0 (en) | Treatment of male sexual dysfunction | |
GB0120679D0 (en) | Treatment of male sexual dysfunction | |
GB0106167D0 (en) | Treatment of male sexual dysfunction | |
GB0316673D0 (en) | Treatment of female sexual dysfunction | |
GB0221712D0 (en) | Methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |